Purchase this article with an account.
Alessandro Rabiolo, Ilaria Zucchiatti, alessandro marchese, Giovanni Baldin, Riccardo Sacconi, Daniela Montorio, Maria Vittoria Cicinelli, Lea Querques, Giuseppe Querques, Francesco Bandello; OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH EPLERENONE OR PHOTODYNAMIC THERAPY. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1645.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (i.e. oral eplerenone, half-fluence photodynamic therapy [PDT]).
Twenty eyes of 16 consecutive patients with treatment-naïve CSC undergoing either eplerenone or PDT were enrolled in this prospective, observational study. All patients underwent structural OCT and OCT-A at baseline and after therapy at months 1 and 3.
Eleven eyes of 9 patients and 9 eyes of 7 patients underwent eplerenone or PDT treatment, respectively. Central macular thickness (CMT) and subretinal fluid (SRF) correlated to fovea avascular zone (FAZ) area (r = 0.74 and r = 0.71, p = 0.01) and vessel density (r = 0.77 and r = 0.68, p = 0.01) at deep capillary plexus (DCP). CMT (p = 0.0011), SRF (p = 0.0005), SFCT (p = 0.0016), FAZ area at DCP (p = 0.0334) improved at 3-month visit. A significant reduction of deep FAZ area was appreciated in Eplerenone (p = 0.0204) but not in PDT (p = 0.5) group. SFCT reduction was significantly higher in PDT than eplerenone group (p = 0.0347).
Structural and vascular parameters are correlated in CSC and they improve after different treatments. Both half-fluence PDT and oral eplerenone do not permanently damage choriocapillaris or other choroidal layers as evaluated by OCT-A. SFCT decreases with both treatments, although the change is more pronounced following half-fluence PDT.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only